Inhibition of the JAK/STAT pathway, particularly through JAK1/2 inhibitors like ruxolitinib, offers a promising therapeutic strategy in PAH by reducing vascular remodeling, counteracting CAV1 deficiency-induced endothelial dysfunction, and limiting aberrant STAT3-driven endothelial proliferation in IPAH.27,317,319. This evidence concerns the gene STAT3 and idiopathic pulmonary arterial hypertension.